Navigation Links
International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
Date:9/27/2007

. regulatory authorities. ''Our ultimate goal is to see NeuroAid(TM) included in key treatment guidelines for stroke victims, making its benefits available to all patients who need it,'' David added.

NeuroAid(TM)'s efficacy and safety was tested in a multi-centre double blind randomized clinical trial conducted on 605 patients in China in 1999- 2000. Patients taking NeuroAid(TM) were shown to be 2.11 times more likely to reach functional independence and 1.7 times more likely to reduce their neurological deficit by at least 55% than patients who did not take the product. It helped improve stroke patients' ability to recover even when treatment was started several weeks after the onset of stroke.

About NeuroAid(TM)

NeuroAid(TM) is a Traditional Chinese Medicine that provides faster and more extensive recovery of motor and cognitive functions in stroke patients during rehabilitation. It is a combination of fourteen all-natural ingredients from the Chinese medicinal pharmacopoeia, formulated according to international Good Manufacturing Practice (GMP) standards. It is marketed internationally by Moleac, the biopharmaceutical company that identified the product in China as the first medicine to help improve stroke recovery. NeuroAid(TM) is currently marketed in Singapore as a Chinese proprietary medicine, and in other countries in the region as a dietary supplement. It is also sold internationally by Moleac via the website http://www.neuroaid.com . With the CHIMES study, NeuroAid(TM) is the first traditional medicine in the world to be studied in a large scale evidence-based clinical trial.

About Moleac

Moleac is a biopharmaceutical company based in Biopolis, a world-class purpose built complex for biomedical sciences research in Singapore ( http://www.biopolis.com.sg ). Moleac identifies promising medicines discovered in China and dev
'/>"/>

SOURCE Moleac
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... PARIS, November 6 , - ...Linezolid for the,Treatment of Multi-Resistant Sta...vexel, a speciality pharmaceutical company focused...tics designed to overcome the significant global,p...at its most advanced oral,antibacterial NXL103 (fl...
(Date:11/5/2009)...OINT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCal...PT ), a specialty pharmaceutical company focused o...tary products that address important therapeutic n... it will host a webcast and teleconference with ma...esults on Thursday, November 12, 2009, at 5:00 p.m...
(Date:11/5/2009)...ULLERTON, Calif., Nov. 5 Renee Cob...ate professor of dermatology at the University of ...nts are experiencing tremendous results with Therm...ed for skin tightening and contouring, features a ...efficacy and improves patient comfort. ,, "The...
Breaking Medicine Technology:Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R) 2What are the most effective ways of promoting physical exercise in adults 3F 51564 1What are the most effective ways of promoting physical exercise in adults 3F 51564 2What are the most effective ways of promoting physical exercise in adults 3F 51564 3Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 1Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 2Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 3Novel drug discovery tool could identify promising new therapies for Parkinsons disease 13001 4Pelosi Statement on Appointment of Dr Regina Benjamin as Surgeon General of the United States 51560 1
...or Cancer Research meeting indicate that technolo...-water-soluble drugs to treat cancer and possibly ...r Pharmaceuticals today,reported results on a nove...pable of dissolving in water (hydrophobic drugs) i...ation. These findings allow the company to,combine...
...MOND, Va., April 16 Insmed Inc. (Nasdaq:,INSM), a...ticals, today,announced that it has received appro...care products Regulatory Agency (MHRA) to initiate...n biologic (FOB) product candidate.,Insmed,s INS-1...a follow-on,biologic of the FDA-approved product N...
Other Medicine Technology:Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations 2Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations 3Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 2Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 3Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R) 4
(Date:11/7/2009)...GTON, Nov. 7 The U.S. b...presentatives to vote for the Stupak-Ellsworth Ame...k-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith...on abortion funding and conscience protections in ...962)," they said. ,, The letter was signed by C...
(Date:11/7/2009)...Nov. 7 Americans United for Life Action endorses ...Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith A...ey from going to abortion in health care reform. ,... CEO Dr. Charmaine Yoest said, "Americans United f...rth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendme...
(Date:11/7/2009)... not assume that all youth will rebel, expert says...Teens are more likely to behave badly if their par... "Parents who believe they are simply being realis... prophecy," Christy Buchanan, a psychology profess...study, said in a university news release. "Negativ...
(Date:11/7/2009)... October 23-25th marked the 12th annua...ties fighting the battle against pediatric cancer....ion and it,s efforts for many years. , ...r 7, 2009 -- The weekend of October 23-25 marked ...rs and celebrities fighting the battle against ped...
(Date:11/7/2009)... Forget ‘sweatox’ or &lsqu...is the usage of the anti-ageing jab ‘Breasto...cted into the décolletage, can reduce the a...st area around the breasts, leaving smoother, youn...B) November 7, 2009 -- Transform, the UK’s l...
Breaking Medicine News(10 mins):Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 3Health News:UK Boobs Get a Boost with 'Breastox' 2
...Ohio, Jan. 30 Cardinal Health Chief,Executive Off...erbeck, will,address investors at the Merrill Lync... Device Conference in New York on Feb. 7 at 9:20 a...ntinued growth. His,remarks will be webcast live. ...
...TI, Jan. 30 , CALL DATE: Wednesday, F...tern Time HOST: Dr. Candace Kend... conduct a telephone conference call and,simultane...wer session will follow., (Logo: http://www.news...
...ealthcare to Offer Unique and Cost-Effective Appro... Clinical Outcomes, TORONTO and PHOENIX, Jan. 30 ...ns and health information solution provider,based ...n Phoenix, Arizona, to provide its innovative inte...
...Mich., Jan. 30 The Michigan Business and,Professi...ociation Michigan,Food and Beverage Association (M...at employ over 180,000 individuals throughout the ... Senate,approval. "With today,s economy in mind, w...
...nt and Vestar Capital Partners Purchase Interest f...al Partners, SOUTH BEND, Ind. and NEW YORK, Jan. ...ider of health care performance,improvement soluti...Securities Capital Partners, LLC (ASCP). The,Press...
...CITY, Calif. and FORT LAUDERDALE, Fla., Jan. 30, C...,its innovative C-Port(R) Distal Anastomosis Syste...acic surgeons at the 2008 STS University. In,addit...eting of The Society of Thoracic Surgeons (STS) in...
Other Medicine News:Health News:Cardinal Health CEO of Clinical & Medical Products to Speak at Merrill Lynch's Global Pharmaceutical, Biotechnology and Medical Device Conference 2Health News:Kendle Invites You to Attend Its Fourth Quarter and Year End 2007 Earnings Conference Call and Webcast 2Health News:Life:WIRE(TM) to Provide Action Healthcare Management with Innovative Mobile Health Management Solution for Patients with Chronic Conditions 2Health News:Individual Healthcare Reform Necessity in New Business Economy 2Health News:Press Ganey Takes on New Investment Partner 2Health News:Press Ganey Takes on New Investment Partner 3Health News:Press Ganey Takes on New Investment Partner 4Health News:Cardica's C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University 2Health News:Cardica's C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University 3
Cruchfield Skull Traction Tong
...ll base surgery. Complete implant selection for: c... pediatric neurosurgery, bony defects of the masto...o trauma. Dedicated neuro/skull base system combin...RI and CT compatible implants. Available with the ...
Crutchfield Skull Traction Tong
Ralk Hand Drill
Medicine Products: